(Date:11/21/2008)...swire-FirstCall/ -- The Providence Service,Corpor... A. Norris, the Company,s,Chief Operating Officer...rectors. Mr. Norris, appointment fills the vacanc... Geringer and returns the board to six members. M...Board. , Mr. Norris, age 41, has been with ...
(Date:11/21/2008)... a novel technique to combat cancer, study says,...- Belgian researchers have discovered that some ca...od, and this might lead to new treatments that sta...iferate, all cells in the body need to produce ene...ocess that requires oxygen. Compared with normal c...
(Date:11/21/2008)...Vigorously Protect Investment And Restore Sharehol...re-USNewswire/ -- Dr. Stephen Joffe, Craig Joffe, ...Schedule 13D with the U.S. Securities and Exchange...closing ownership of 11.4% of LCA-Vision, Inc. (Na...site laser vision correction centers in 33 states ...
(Date:11/21/2008)...wswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (N... overwhelmingly approved the proposals submitted t... Pharmaceuticals Industries Ltd. (Nasdaq: TEVA )...helming support of the transaction by the Barr sha...and CEO. "We are pleased with the progress that we...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4...ncluding senior doctors and other dignitaries pled...R), here today. Amongst// others, Ms Nikita Anand ...ma Chona, Principal DPS, RK Puram, New Delhi, Mr A...uth poles and eminent media personality Col Ajai S...
... personnel reveals that for food-allergic consumer...ize//. The first-of-its-kind study was published ...gy, the scientific journal of the American College...unology (ACAAI). Ryan Ahuja and Scott H. Sicherer...
...erized by an insufficiency in the amount or qualit... suffer from DES, it can get in the way of daily l...n most people, a constant tear film lubricates and..., a decreased production of fluid can weaken the t...
...mnity and respectability about it. For a British m...// track of the movement of the elderly with demen...ative suggestion for keeping track of people affli...tronically tagged, says UK Science Minister Malcol...
Other Medicine News:Health News:Dining Out is Risky for Food-allergic Consumers 2Health News:Dry Eyes Are More Than a Nuisance 2Health News:Electronic Tagging - for the Elderly Now! 2(Date:11/20/2008)...if., Nov. 20 Duska Thera...ced today that it has submitted its,pivotal Phase... a Special,Protocol Assessment (SPA) procedure wi..., Subject to securing an agreement with the ...ive, double-blind, placebo-controlled and randomiz...
(Date:11/20/2008)...orway, November 20 The Scandinavia...has announced results of studies on its,lead anti... Washington, DC,the studies showed that the nove...ocidal effect, significantly better towards killin...s than marketed gold standard drugs. In,addition ...
(Date:11/19/2008)...ntists report basic findings on critical enzyme,s ...tter treat an array of disorders , , MEMPHI...ntists at St. Jude Children,s Research Hospital ha...he body,s enzyme workhorses called calpains. , ...ains function in many cellular processes, includin...
(Date:11/18/2008)...ber 19 NeuroDiscovery Lt...ovider and drug development Company,and Sosei Gr..., a leading,international biopharmaceutical compa...ing further pivotal pre-clinical efficacy data for...tential therapy for neuropathic pain and has,succ...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Study identifies genetic risk factor for rheumatoid arthritis lupus 294 1Study identifies genetic risk factor for rheumatoid arthritis lupus 294 2Study identifies genetic risk factor for rheumatoid arthritis lupus 294 3Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases 291 1Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases 291 2Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases 291 3Filtered Cigarettes Blamed for Huge Rise in Type of Lung Cancer 689 1Filtered Cigarettes Blamed for Huge Rise in Type of Lung Cancer 689 2Filtered Cigarettes Blamed for Huge Rise in Type of Lung Cancer 689 3Filtered Cigarettes Blamed for Huge Rise in Type of Lung Cancer 689 4Dont just save her life save her fertility 686 1Dont just save her life save her fertility 686 2Dont just save her life save her fertility 686 3Dont just save her life save her fertility 686 4Dont just save her life save her fertility 686 5Dont just save her life save her fertility 686 6...007 - Pro-Pharmaceuticals,Inc. (Amex: PRW), a com...day updated the progress of its Phase II,clinical ...sectable,colorectal cancer patients who are unable...s Phase II clinical trial for first-line,treatment...dications may represent orphan drug status for DAV...
...y to Show That Extended,Thromboprophylaxis Reduces...tatistically Significant 44% , PARIS, July 8, 2007... today the results of the EXCLAIM (EXtended CLinic...udy, which showed,the benefit of extended prophyla...obility by demonstrating the superiority of 5 week...
Other Medicine Technology:Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 2Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 3Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 4Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: